Jiahui International Cancer Center welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment of a solid tumor.
Approved by China's National Medical Products Administration (NMPA), Satri-cel is indicated for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. The approval represents a landmark achievement not only for patients with advanced gastric cancer, but also for the global field of cancer treatment.
A New Chapter for Solid Tumor Treatment
CAR-T cell therapy has transformed outcomes for many patients with blood cancers over the past decade. However, successfully applying CAR-T technology to solid tumors has long been considered one of oncology's greatest challenges.
The approval of Satri-cel marks the first time a CAR-T therapy for a solid tumor has successfully reached the market, opening a new chapter in cellular immunotherapy and offering new hope to patients with advanced gastric cancer.
In the pivotal clinical trial supporting approval, Satri-cel demonstrated meaningful improvements in response rates, disease control and survival outcomes in heavily pre-treated patients: 41% of treated patients saw measurable tumor shrinkage, compared to only 4% on standard therapy, and the therapy extended median overall survival by nearly six months for this hard-to-treat group.The therapy also showed a manageable safety profile, further supporting its clinical value.
China's Growing Role in Global Oncology Innovation
This milestone also reflects the rapid rise of China's biomedical innovation ecosystem.
In recent years, China has become an increasingly important source of novel oncology therapies, clinical research and treatment innovation. The approval of the world's first solid tumor CAR-T therapy further reinforces China's position at the forefront of next-generation cancer treatment development.
As international awareness of Chinese medical innovation continues to grow, more physicians, researchers and patients around the world are looking to China for access to novel therapies and treatment options.
Access Through Jiahui International Cancer Center
At Jiahui International Cancer Center (JICC), we are committed to connecting patients with the latest advances in cancer care.
JICC offers comprehensive oncology services spanning medical oncology, surgical oncology, radiation oncology, precision medicine, and advanced cellular therapies. Through our multidisciplinary care model and close collaboration with leading oncology experts, we strive to ensure that eligible patients can access innovative treatments in a safe, coordinated and patient-centered manner.
For international patients, JICC provides dedicated support throughout the treatment journey, including medical record review, specialist consultations, multilingual coordination, treatment planning, logistics assistance and ongoing follow-up care.
As global interest in innovative therapies such as CAR-T continues to grow, JICC remains committed to serving as a bridge between patients worldwide and the latest developments in cancer treatment.
Looking Ahead
The approval of Satri-cel is more than a regulatory milestone. It is a historic moment for cancer medicine and an important step toward expanding the role of cellular therapies in solid tumors.
For patients, physicians and researchers around the world, it represents a glimpse into the future of oncology—one in which innovative therapies continue to push the boundaries of what is possible in cancer care.
Contact the International Office
Email: internationaloffice@jiahui.com
Whatsapp: +852 4619 1904
